Patents by Inventor Stephen W Kaldor

Stephen W Kaldor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID STATE FORMS OF AN FGFR INHIBITOR
    Publication number: 20250059170
    Abstract: The present disclosure relates to solid state forms of 1-((3S,5R)-1-acryloyl-5-(methoxymethyl)pyrrolidin-3-yl)-3-((1-cyclopropyl-4, 6-difluoro-1H-benzo[d]imidazol-5-yl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide. Such solid state forms are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of disease.
    Type: Application
    Filed: December 7, 2022
    Publication date: February 20, 2025
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Andrew PHIMISTER, Jayachandra P. REDDY, John TYHONAS, Shubham CHOPADE, Preetanshu PANDEY, Jason M. COX, Robert KANIA
  • SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS
    Publication number: 20240400569
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: May 2, 2024
    Publication date: December 5, 2024
    Inventors: Robert L. HOFFMAN, Porino Jinjo VA, Joseph Robert PINCHMAN, Qing DONG, Stephen W. KALDOR
  • Pyridinone MK2 inhibitors and uses thereof
    Patent number: 12139462
    Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: May 2, 2023
    Date of Patent: November 12, 2024
    Assignee: XinThera, Inc.
    Inventors: Robert L. Hoffman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • PARP1 INHIBITORS AND USES THEREOF
    Publication number: 20240368162
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 7, 2024
    Inventors: Qing DONG, Robert L. HOFFMAN, Stephen W. KALDOR, Joseph Robert PINCHMAN, Lynnie TRZOSS, Porino Jinjo VA
  • Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors
    Patent number: 12060343
    Abstract: Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: August 13, 2024
    Assignee: Alumis Inc.
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • SOLID STATE FORMS OF (S)-N-(3-(2-(((R)-1-HYDROXYPROPAN-2-YL)AMINO)-6-MORPHOLINOPYRIDIN-4-YL)-4-METHYLPHENYL)-3-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SALTS THEREOF
    Publication number: 20240208931
    Abstract: The present disclosure relates to solid state forms of (S)-N-(3-(2-(((R)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof. Such solid state forms are useful in preparation of pharmaceutical compositions and dosage forms for the treatment of disease.
    Type: Application
    Filed: April 21, 2022
    Publication date: June 27, 2024
    Inventors: Stephen W. KALDOR, Toufike KANOUNI, Andrew PHIMISTER, Jayachandra P. REDDY
  • Substituted pyridazines as TYK2 inhibitors
    Patent number: 12006306
    Abstract: Described herein are compounds, for example, substituted pyridazines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: June 11, 2024
    Assignee: Alumis Inc.
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • Substituted pyridines as PARP1 inhibitors
    Patent number: 12006322
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors.
    Type: Grant
    Filed: September 20, 2023
    Date of Patent: June 11, 2024
    Assignee: Xin Thera, Inc.
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Qing Dong, Stephen W. Kaldor
  • Inhibitors of lysine specific demethylase-1
    Patent number: 11987560
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: May 21, 2024
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • MK2 inhibitors and uses thereof
    Patent number: 11987574
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Grant
    Filed: July 13, 2023
    Date of Patent: May 21, 2024
    Assignee: XinThera, Inc.
    Inventors: Lynnie Trzoss, Qing Dong, Stephen W. Kaldor, Robert L. Hoffman
  • SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS
    Publication number: 20240109904
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: September 20, 2023
    Publication date: April 4, 2024
    Inventors: Robert L. HOFFMAN, Porino Jinjo VA, Joseph Robert PINCHMAN, Qing DONG, Stephen W. KALDOR
  • PARP1 inhibitors and uses thereof
    Patent number: 11939329
    Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: March 26, 2024
    Assignee: XinThera, Inc.
    Inventors: Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor
  • SUBSTITUTED 1,2,4-TRIAZOLES AS INTERMEDIATES IN THE SYNTHESIS OF TYK2 INHIBITORS
    Publication number: 20230391751
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: June 15, 2023
    Publication date: December 7, 2023
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • PYRIDINONE MK2 INHIBITORS AND USES THEREOF
    Publication number: 20230382864
    Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 30, 2023
    Inventors: Robert L. HOFFMAN, Lynnie TRZOSS, Qing DONG, Stephen W. KALDOR
  • MK2 INHIBITORS AND USES THEREOF
    Publication number: 20230373969
    Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.
    Type: Application
    Filed: July 13, 2023
    Publication date: November 23, 2023
    Inventors: Lynnie TRZOSS, Qing DONG, Stephen W. KALDOR, Robert L. HOFFMAN
  • INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
    Publication number: 20230374015
    Abstract: Provided herein are heteroaryl inhibitors of fibroblast growth factor receptor kinases, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Application
    Filed: June 4, 2021
    Publication date: November 23, 2023
    Inventors: Stephen W. KALDOR, John TYHONAS, Eric A. MURPHY, Toufike KANOUNI, Lee D. ARNOLD, Robert KANIA
  • SUBSTITUTED PYRIDINES AS PARP1 INHIBITORS
    Publication number: 20230348473
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 2, 2023
    Inventors: Robert L. HOFFMAN, Porino Jinjo VA, Joseph Robert PINCHMAN, Qing DONG, Stephen W. KALDOR
  • Azetidine and pyrrolidine PARP1 inhibitors and uses thereof
    Patent number: 11802128
    Abstract: Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors.
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: October 31, 2023
    Assignee: Xinthera, Inc.
    Inventors: Robert L. Hoffman, Qing Dong, Stephen W. Kaldor, Lynnie Trzoss, Porino Jinjo Va
  • Substituted pyridines as PARP1 inhibitors
    Patent number: 11795173
    Abstract: Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors.
    Type: Grant
    Filed: April 27, 2023
    Date of Patent: October 24, 2023
    Assignee: Xinthera, Inc.
    Inventors: Robert L Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Qing Dong, Stephen W. Kaldor
  • Inhibtors of RAF kinases
    Patent number: 11746095
    Abstract: Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 5, 2023
    Assignee: KINNATE BIOPHARMA INC.
    Inventors: Stephen W. Kaldor, Toufike Kanouni, Eric Murphy, Jason Cox, Robert Kania